A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+metastatic breast cancer (MBC)

被引：1
|
作者：
Jhaveri, Komal L.
Hamilton, Erika Paige
Miller, Kathy
Roche, Maria
Berger, Mark S.
Winer, Eric P.
Lin, Nancy U.
机构：
[1] NYU, Inst Canc, New York, NY USA
[2] Sarah Cannon Res Inst, Brentwood, Essex, England
[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Kadmon Corp, Wilmington, MA USA
[5] Kadmon Corp, New York, NY USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
608
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer (MBC) with brain metastases (BM) (HER2CLIMB)
    Mueller, V
    Lin, N.
    Murthy, R.
    Anders, C.
    Borges, V
    Hurvitz, S.
    Loi, S.
    Abramson, V
    Bedard, P.
    Oliveira, M.
    Zelnak, A.
    Di Giovanna, M.
    Bachelot, T.
    Chien, A. J.
    O'Regan, R.
    Wardley, A.
    Carey, L.
    McGoldrick, S.
    An, X.
    Winer, E. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 161 - 161
  • [23] Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+metastatic breast cancer (MBC)
    Lee, Soo-Chin
    Chin, Si Yin
    Shimasaki, Noriko
    Tan, Lip Kun
    Koh, Liang Piu
    Lieow, Jedidah J. M.
    Kono, Koji
    Kwan, Hsueh Yin
    Coustan-Smith, Elaine
    Wong, Andrea Li Ann
    Soo, Ross A.
    Tan, Belinda
    Poon, Michelle Li Mei
    Yap, Yoon Sim
    Yong, Wei-Peng
    Goh, Boon C.
    Campana, Dario
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Laura M. Spring
    Shealagh L. Clark
    Tianyu Li
    Shom Goel
    Nabihah Tayob
    Elene Viscosi
    Elizabeth Abraham
    Dejan Juric
    Steven J. Isakoff
    Erica Mayer
    Beverly Moy
    Jeffrey G. Supko
    Sara M. Tolaney
    Aditya Bardia
    npj Breast Cancer, 7
  • [25] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Spring, Laura M.
    Clark, Shealagh L.
    Li, Tianyu
    Goel, Shom
    Tayob, Nabihah
    Viscosi, Elene
    Abraham, Elizabeth
    Juric, Dejan
    Isakoff, Steven J.
    Mayer, Erica
    Moy, Beverly
    Supko, Jeffrey G.
    Tolaney, Sara M.
    Bardia, Aditya
    NPJ BREAST CANCER, 2021, 7 (01)
  • [26] Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC).
    Miller, KD
    Burstein, HJ
    Elias, AD
    Rugo, HS
    Cobleigh, MA
    Pegram, MD
    Eisenberg, PD
    Collier, M
    Adams, BJ
    Baum, CM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 19S - 19S
  • [27] Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer
    Iwase, Toshiaki
    Damodaran, Senthil
    Marx, Angela
    Meric-Bernstam, Funda
    Tripathy, Debashish
    Barcenas, Carlos Hernando
    Lee, Jangsoon
    Ueno, Naoto Tada
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC).
    Miller, KD
    Burstein, HJ
    Elias, AD
    Rugo, HS
    Cobleigh, MA
    Wolff, AC
    Eisenberg, PD
    Collier, M
    Adams, BJ
    Baum, CM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S61 - S61
  • [29] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients ( pts) with HER2+metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA)
    Yao, H.
    Shi, Y.
    Yao, Y.
    Li, H.
    Zhou, H.
    Wang, S.
    Qin, Q.
    Li, W.
    Geng, C.
    Wang, M.
    Wang, X.
    Cao, Y.
    Yu, Z.
    Du, C.
    Zhao, W.
    Wu, S.
    Cui, Y.
    Liu, P.
    Lin, J.
    Song, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 50 - 51
12345